⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NAMS News
NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
globenewswire.com
NAMS
NewAmsterdam Pharma und die Menarini Group erhalten positive Stellungnahme des CHMP mit der Empfehlung zur Erteilung einer Zulassung für Ubeslo® (Obicetrapib-Monotherapie) und Evlarco® (Festsatzkombination aus Obicetrapib und Ezetimib)
prnewswire.com
NAMS
NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo® (obicetrapib en monothérapie) et d'Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
prnewswire.com
NAMS
NewAmsterdam Pharma y Menarini Group reciben una opinión positiva del CHMP sobre Ubeslo®
prnewswire.com
NAMS
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
prnewswire.com
NAMS
Form 8-K
sec.gov
NAMSW
NAMS
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
globenewswire.com
NAMS
Form 8-K
sec.gov
NAMSW
NAMS
Attovia Therapeutics Appoints John W. Smither to Board of Directors
globenewswire.com
MBX
ARQT
NAMS
GNLX
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
NAMS